When changes are made to testing requirements, methodologies, etc., Wisconsin Diagnostic Laboratories strives to keep you informed as soon as possible so we can provide the highest quality service to you.
To open documents, simply click on the link for more information.
Effective Sept. 26, 2019, Wisconsin Diagnostic Laboratories (WDL) will begin offering the American Medical Association (AMA) approved Obstetric Panel with HIV. This panel combines the currently available Obstetric Panel and the HIV 1/2 Ag/Ab, 4th Generation test.
Effective Sept. 18, 2019, WDL will begin offering a new panel combining the current Volatile Alcohol Panel and Ethylene Glycol tests. This new test panel, named Volatile Alcohol + Ethylene Glycol Screen (mnemonic VOLAT GLYC), will become the preferred first-line screening test when ingestion of any alcohol or glycol is suspected.
Effective Sept. 10, 2019, WDL will be implementing a new FDA-approved test for detection and quantitation of Cytomegalovirus DNA in plasma.
Effective Aug. 29, 2019, Mycoplasma pneumoniae Antibody (combined IgG and IgM) and Mycoplasma pneumoniae IgM testing will be inactivated in Epic due to poor specificity of the test.
Effective June 4, 2019, WDL is implementing a new Coagulation Instrument System in the WDL Main Lab only. Reference ranges and reportable rangeswill change for PTT, PTT HEP, FIBRGN, D DIMER, and PT. Also, please note,PTT specimen stability is changing from 24 hours to 4 hours.